Market Closed -
Canadian Securities Exchange
20:38:22 24/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.235
CAD
|
-2.08%
|
|
-2.08%
|
-7.84%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3.185
|
3.306
|
13.36
|
30.54
|
15.65
|
15.37
|
Enterprise Value (EV)
1 |
3.149
|
3.286
|
12.76
|
29.79
|
17.23
|
16.95
|
P/E ratio
|
-4.21
x
|
-6.14
x
|
-10.8
x
|
-26.7
x
|
-9.98
x
|
-8.29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
50,736,829
x
|
-
|
356,209,178
x
|
100,126,793
x
|
EV / Revenue
|
-
|
-
|
48,445,990
x
|
-
|
392,262,031
x
|
110,415,720
x
|
EV / EBITDA
|
-
|
-
|
-10,869,811
x
|
-29,056,266
x
|
-13,486,708
x
|
-9,276,188
x
|
EV / FCF
|
-6.7
x
|
-131
x
|
-223
x
|
-70.9
x
|
-27
x
|
-47.7
x
|
FCF Yield
|
-14.9%
|
-0.76%
|
-0.45%
|
-1.41%
|
-3.71%
|
-2.1%
|
Price to Book
|
-3.54
x
|
-2.71
x
|
-30.4
x
|
-386
x
|
-24.6
x
|
-13.4
x
|
Nbr of stocks (in thousands)
|
62,794
|
65,015
|
72,314
|
76,784
|
77,974
|
83,286
|
Reference price
2 |
0.0507
|
0.0509
|
0.1847
|
0.3978
|
0.2007
|
0.1845
|
Announcement Date
|
30/07/18
|
29/07/19
|
22/07/20
|
14/07/21
|
11/07/22
|
31/07/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.2633
|
-
|
0.0439
|
0.1535
|
EBITDA
|
-
|
-
|
-1.173
|
-1.025
|
-1.278
|
-1.827
|
EBIT
1 |
-0.6606
|
-0.5269
|
-1.185
|
-1.028
|
-1.284
|
-1.84
|
Operating Margin
|
-
|
-
|
-450.22%
|
-
|
-2,922.5%
|
-1,198.95%
|
Earnings before Tax (EBT)
1 |
-0.7267
|
-0.5456
|
-1.215
|
-1.094
|
-1.454
|
-1.842
|
Net income
1 |
-0.7267
|
-0.5456
|
-1.215
|
-1.094
|
-1.454
|
-1.842
|
Net margin
|
-
|
-
|
-461.59%
|
-
|
-3,309.36%
|
-1,200.21%
|
EPS
2 |
-0.0120
|
-0.008277
|
-0.0170
|
-0.0149
|
-0.0201
|
-0.0223
|
Free Cash Flow
1 |
-0.4702
|
-0.025
|
-0.0571
|
-0.4199
|
-0.6394
|
-0.3553
|
FCF margin
|
-
|
-
|
-21.7%
|
-
|
-1,455.47%
|
-231.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/07/18
|
29/07/19
|
22/07/20
|
14/07/21
|
11/07/22
|
31/07/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
1.58
|
1.58
|
Net Cash position
1 |
0.04
|
0.02
|
0.6
|
0.76
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.24
x
|
-0.8644
x
|
Free Cash Flow
1 |
-0.47
|
-0.03
|
-0.06
|
-0.42
|
-0.64
|
-0.36
|
ROE (net income / shareholders' equity)
|
74%
|
51.5%
|
147%
|
422%
|
407%
|
206%
|
ROA (Net income/ Total Assets)
|
-904%
|
-762%
|
-221%
|
-80.8%
|
-66.2%
|
-104%
|
Assets
1 |
0.0804
|
0.0716
|
0.5511
|
1.355
|
2.196
|
1.765
|
Book Value Per Share
2 |
-0.0100
|
-0.0200
|
-0.0100
|
-0
|
-0.0100
|
-0.0100
|
Cash Flow per Share
2 |
0
|
0
|
0.0100
|
0.0100
|
0
|
0
|
Capex
1 |
0
|
-
|
0
|
-
|
0.06
|
0.01
|
Capex / Sales
|
-
|
-
|
0.3%
|
-
|
134.75%
|
3.45%
|
Announcement Date
|
30/07/18
|
29/07/19
|
22/07/20
|
14/07/21
|
11/07/22
|
31/07/23
|
|
1st Jan change
|
Capi.
|
---|
| -40.31% | 7.63B | | +8.65% | 3.61B | | -0.25% | 2.36B | | -24.56% | 1.86B | | -18.21% | 1.74B | | +5.95% | 913M | | +16.75% | 763M | | -10.48% | 678M | | -0.60% | 290M |
Bio Diagnostics & Testing
|